Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study

OBJECTIVE: Due to a high efficacy in clinical trials, sofosbuvir (SOF) and ribavirin (RBV) for 12 or 16 weeks is recommended for treatment of patients with HCV genotype (GT) 2 infection. We investigated safety and effectiveness of these regimens for GT2 in HCV-TARGET participants. DESIGN: HCV-TARGET...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Gut
Hlavní autoři: Welzel, Tania M, Nelson, David R, Morelli, Giuseppe, Di Bisceglie, Adrian, Reddy, Rajender K, Kuo, Alexander, Lim, Joseph K, Darling, Jama, Pockros, Paul, Galati, Joseph S, Frazier, Lynn M, Alqahtani, Saleh, Sulkowski, Mark S, Vainorius, Monika, Akushevich, Lucy, Fried, Michael W, Zeuzem, Stefan
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2017
Témata:
Hepatology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5595101/
https://ncbi.nlm.nih.gov/pubmed/27418632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2016-311609
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky